BRISTOL-MYERS SQUIBB COMPANY Proceeds and Excess Tax Benefit from Share-based Compensation
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Proceeds and Excess Tax Benefit from Share-based Compensation of $7.00 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-10-27.
Discontinued › Notes › Compensation Related Costs
us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation · last filed 2021-10-27
- BRISTOL-MYERS SQUIBB COMPANY proceeds and excess tax benefit from share-based compensation for the quarter ending 2021-09-30 was $7.00M, a 600.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY proceeds and excess tax benefit from share-based compensation for the quarter ending 2021-06-30 was $12.00M, a 140.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY proceeds and excess tax benefit from share-based compensation for the quarter ending 2021-03-31 was $17.00M, a 26.09% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY proceeds and excess tax benefit from share-based compensation for the quarter ending 2020-09-30 was $1.00M.
| Period end | Proceeds and Excess Tax Benefit from Share-based Compensation 3 month | Proceeds and Excess Tax Benefit from Share-based Compensation 6 month | Proceeds and Excess Tax Benefit from Share-based Compensation 9 month |
|---|---|---|---|
| 2021-09-30 | $7.00M 10-Q · filed 2021-10-27 | $19.00M derived: sum of 2 quarters · filed 2021-10-27 | $36.00M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $12.00M 10-Q · filed 2021-07-28 | $29.00M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $17.00M 10-Q · filed 2021-04-29 | ||
| 2020-09-30 | $1.00M 10-Q · filed 2021-10-27 | $6.00M derived: sum of 2 quarters · filed 2021-10-27 | $29.00M 10-Q · filed 2021-10-27 |
| 2020-06-30 | $5.00M 10-Q · filed 2021-07-28 | $28.00M 10-Q · filed 2021-07-28 | |
| 2020-03-31 | $23.00M 10-Q · filed 2021-04-29 | ||
| 2019-03-31 | $2.00M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |